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Abstract
Background—Obtaining the definitive data necessary to determine the safety and efficacy of
using antiretroviral treatment (ART) to reduce the sexual transmission of HIV in heterosexual
couples encountered an array of ethical challenges that threatened to compromise HPTN 052, the
multinational clinical trial addressing this issue that has profound public health implications.
Purpose—To describe and analyze the major ethical challenges faced in HPTN 052.
Methods—The ethical issues and modifications of HPTN 052 in response to these issues were
catalogued by the principal investigator, the lead coordinator, and the ethicist working on the trial.
The major ethical issues that were unique to the trial were then described and analyzed, referring
as appropriate to published literature and emerging guidance and policies. Ethical challenges that
must be addressed in many clinical trials, such as those related to obtaining informed consent and
making provisions for ancillary care, are not described.
Results—When HPTN 052 was being designed, ethical questions emerged related to the
relevance of the research question itself given data from observational research and a range of
beliefs about the appropriate means of preventing and treating HIV-infection and AIDS. Further,
ethical challenges were faced regarding site selection since there was a scientific need to conduct
the research in settings where HIV incidence was high, but alternatives to study participation
should be available. As in most HIV prevention research, ethical questions surrounded the
determination of the appropriate prevention package for all of those enrolled. During the course of
the trial, guidance documents and policies emerged that were of direct relevance to the research
questions, calling for a balancing of concerns for the research subjects and trial integrity. When
the study results were made public, there was a need to ensure access to the treatment shown to be
effective that in some cases differed from the guidelines used at the sites where the research was
being conducted. In addition, questions were raised about whether there was an obligation to
notify subjects about “unlinked’ transmissions of HIV, that is, infections acquired outside of the
designated sexual partners enrolled in the study.
Limitations—The ethical issues described are limited to those discerned by the authors and not
those of other stakeholders who may have identified additional issues or had a different
perspective in analyzing them.
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Conclusions—Understanding the ethical challenges faced in HPTN 052 promises to inform the
design and conduct of future complex, long-term clinical trials aimed at addressing critical
scientific and public health questions, where data and practice patterns emerge over the course of
the trial.
Introduction
After years of speculation and debate, definitive data now indicate that the use of
antiretroviral treatment (ART) in persons who are HIV-infected can reduce transmission of
HIV to their heterosexual partners.1 This finding has profound global implications. While
the publication of the results of HIV Prevention Trials Network (HPTN) 052, the
multinational trial that demonstrated these salutary results, is widely heralded as a success,
from its outset the trial faced a series of ethical challenges that threatened the ability to
answer the primary research questions. These ethical challenges evolved over the course of
the trial and necessitated deliberation and response, not only from the investigators,
sponsors, community members, and oversight bodies, but also from those with expertise in
ethics. Understanding these ethical challenges promises to inform the design and conduct of
future complex, long-term clinical trials aimed at addressing critical scientific and public
health questions where data and practice patterns continue to emerge over the course of the
trial.
HPTN 052 was sponsored by the National Institute of Allergy and Infectious Diseases/
National Institutes of Health (NIAID/NIH) and was designed to address two questions. First,
can ART that suppresses HIV replication prevent sexual transmission of the virus to a sexual
partner? Second, is earlier ART (offered at a high CD4 count) better for personal health?
Accordingly, HPTN 052 involved random assignment to early versus delayed treatment of
HIV. The logistical and practical aspects of designing and implementing the trial are
detailed elsewhere1,2. Briefly the pilot phase (2005–7) enrolled 92 HIV serodiscordant
couples, where the index subject was HIV-infected with a CD4 count between 300–500
cells/mm3 at recruitment and their designated sexual partner was HIV-uninfected; ART in
the delayed arm was offered when the CD4 count fell below 200 cells/mm3, thereby
allowing some time to demonstrate protection by ART in those in the immediate arm. By the
time recruitment began for the full phase of the study (2007), the protocol was modified
with respect to both the CD4 inclusion criteria and the timing for the initiation of ART.
Specifically, upon enrollment, the infected partner was required to have a CD4 count of
350–550 cells/mm3; and ART was initiated in the delayed arm to when two consecutive
CD4 counts below 250 cells/mm3 were observed. Given the medical importance of initiating
ART before the CD4 count reached 200 cells/mm3, CD4 counts were repeated soon after an
initial count was below 250 cells/mm3. These protocol modifications were made by the
study team in response to recommendations from the Data and Safety Monitoring Board
(DSMB) that was well aware of the potential health benefits of initiating ART at a higher
CD4 count. Further, updated World Health Organization (WHO) guidelines were issued in
early 2006, recommending that ART be initiated between 200 – 350 cells/mm3.3 Ultimately,
1763 serodiscordant couples were enrolled at 13 sites in 9 countries.
Initial Ethical Challenges: Study Design, Site Selection, and the Prevention
Package
Study Design
Among others, necessary conditions for research to be ethically acceptable are that a study
appropriately and rigorously designed to address relevant research questions.4 In
randomized clinical trials, such research may rightly involve examining testing interventions
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for which there is a lack of expert consensus on whether one study arm is superior to
another. Some scholars believe that such a state of affairs can be described as “clinical
equipoise”,5 yet others find this notion to be problematic6. While it is beyond the scope of
this paper to defend a particular conceptual approach, it seems fair to say that those on both
sides of the conceptual debate would endorse the ethical requirements delineated above6,7.
As the HPTN 052 protocol was being developed, it was clear that there was a need to
develop means for preventing the sexual transmission of HIV infection as well as to offer
the best treatment for those infected with HIV. While limited data were available concerning
the research questions the study addressed, some experts at the time believed that the
primary research question regarding transmission to a sexual partner had already been
answered based upon a single retrospective observational study that associated blood HIV
viral load and transmission probability in Uganda.8 In other words, the strong biological
plausibility of the idea combined with the observational data suggested to some that a
randomized trial was not required. This belief had to be explicitly considered to ensure that
conducting the proposed research would still be ethically appropriate This in part arguable
involves whether there was clinical equipoise regarding each arm of the study in terms of the
main outcome measures. Note that clinical equipoise permits particular individuals to
disagree that uncertainty remains since under this approach the crucial assessment is
whether there is uncertainty among experts all things considered. Accordingly, it was critical
to recognize the limitations of the findings from the observational Uganda study. First, the
Uganda study did not involve the use of ART, nor did it determine whether apparent HIV
transmission events were virally linked. Since HIV can be acquired outside individual
partnerships1, demonstrating viral linkage is critical. Most importantly, the observational
data from Uganda could not provide insight about the magnitude or durability of benefit
afforded by intervening with ART; however, such data are critical for developing sound
prevention strategies. Ultimately, this information from HPTN 052 regarding the extent to
which ART prevented HIV transmission became a catalytic event for establishing that ART
can help prevent infection with HIV9; at its outset HPTN 052 was poised to help answer
research questions about which there were substantial uncertainty.
Site Selection
In order to answer the primary research question, it was essential to conduct HPTN 052 at
sites that were experiencing high incidence rates of HIV infection. Across much of the world
at the time the study was being designed, high HIV incidence rates were commonplace in
resource constrained settings. As a consequence, as the trial was being designed, ART was
not generally available at most of the research sites, generating claims that the trial might be
“coercive”, since participants would have access to life-saving drugs that otherwise would
not be available to them. While the unavailability of ART at the research sites reflected
longstanding issues of global justice, labeling the trial as coercive was misplaced since
coercion implies a forced bad choice.10 Given what was known about the use of ART at the
time, deciding whether to participate in HPTN 052 did not necessarily require making a
forced bad choice. Similarly, offering enrollment in the trial would not be properly
considered an undue inducement since the offer of participation including access to ART
would not reasonably seem to adversely affect decision-making of potential subjects.11
However, if there was unavailability of ART at the research sites, enrollment would
understandably be considered a strong incentive. Fortunately, the World Health
Organization’s Three by Five Campaign12, the Global Fund to Fight AIDS, Tuberculosis,
and Malaria13 and the President’s Emergency Plan for AIDS Relief (PEPFAR)14 made ART
far more available than it had been before HPTN 052 fully started, so patients with low CD4
counts who unequivocally needed ART generally had access to treatment according to
country guidelines without having to enroll in HPTN 052. It is important to note, however,
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that this typically meant that ART was available for those with very low CD4 counts who
would de facto be ineligible for enrollment in the HPTN 052 study. In addition, in
coordination with NIAID, a separate study (AIDS Clinical Trials Group 5175) was launched
to offer the option of participating in a treatment clinical trial for potential participants who
screened out of HPTN 052 due to CD4 count falling below the threshold required for study
entry.15
The prevention package
Until quite recently, HIV prevention in adults depended entirely on reducing higher risk
behavior through counseling and the provision of condoms. To provide ART without
offering safer sex counseling and condoms in HPTN 052 would suggest that the
investigators and sponsor were not concerned with the well-being of the participants and
were willing to tolerate HIV transmission to address the research questions. Conversely, if
HIV transmission was decreased greatly as a result of counseling and behavior change, the
trial might well prove futile. This tension is commonplace in HIV-prevention trials, yet
including a “prevention package” is ethically obligatory. As discussed in more detail
elsewhere, developing a particular prevention package for a trial should be established with
broad input and include interventions that are known to be effective, reasonably accessible,
and practically achievable.16 In order to ensure the integrity of a trial, it should be powered
appropriately to account for the anticipated prevention benefit from the package. In HPTN
052, couples and adherence counseling was optimized so that the intervention could
reasonably be expected to be effective, accessible and achievable. In addition, the study was
powered to anticipate the very low level of HIV transmission that was actually observed.1
Ethical Challenges during the Study: Evolving Guidelines and Policies
As HPTN 052 was ongoing, there was growing enthusiasm for using ART for prevention, as
well as for initiation of earlier treatment (at a higher CD4 cell count). However, HPTN 052
was the only randomized clinical trial actually addressing these questions. While another
study17 discussed below was organized to address the question of when to initiate ART, the
actual enrollment and management led to the study of a different population. In order to
generate the most orderly clinical and public health recommendations the World Health
Organization has generated a strategy to weigh and employ the strength of evidence18.
Based on available evidence of recognized moderate or low strength, HIV treatment
guidelines were issued that called for changes in current ART practice.19 This evolving
guidance brought into sharp focus the ethical tensions inherent to a moral obligation to
intervene, and the sometimes conflicting need for gathering data to develop evidence-based
practices. Given these guidelines, there was a clear need to deliberate about the protection of
the research subjects, the appropriateness of the HPTN 052 research design including the
continued existence of clinical equipoise, and the integrity of the trial itself. The nature of
these emerging guidelines and policies and their implications for HPTN 052 with respect to
prevention and time to initiate treatment over the course of the trial are discussed below.
ART and HIV transmission
Prior to the results from HPTN 052, two lines of evidence were used to examine the effects
of ART on sexual transmission of HIV: analyses of HIV transmission among serodiscordant
couples in observational studies,20, 21 and population-level ecological studies.22 While most
observational studies support the idea that ART can decrease HIV transmission, not all
population study results have reported a benefit from ART.23, 24 Further, there are clear
limitations of observational and ecologic studies.25 Accordingly, although observational
studies can be useful, the potential for confounding and systematic error should cause great
pause when and if such studies are used to support changes in medical or public health
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policy. The randomized controlled trial method is used specifically to reduce many of these
concerns, leading to a higher level of evidence18. Thus, despite biological plausibility,
evolving data from population studies, and growing interest in using ART for prevention
during the course of the HPTN 052, it remained unclear if this approach was truly safe and
effective, warranting continuation of the trial. While it may seem intuitive that early
initiation of ART might be desirable, untoward side effects in new populations always
require consideration. In addition, the effects of ART on sexual behavior have long been a
concern, with the fear that increased risk behavior might offset the prevention benefit
provided by ART.26 Ultimately, he desire for rigorous data needed to be balanced against
the interests of the subjects; accordingly HPTN 052 included not only plausible approaches
to the prevention of HIV transmission, but also regular systematic monitoring by the DSMB.
When to start ART
At least five observational retrospective studies addressing the optimal time to initiate ART
have been published.24, 27–30 These studies all suggest that ART started at a CD4 count
higher than 200 cells/mm3 reduces morbidity and mortality from HIV infection, but to
differing degrees depending on the methods and the cohorts. The greatest disagreements in
these reports surface when ART is initiated at CD4 counts greater than 500 cells/mm3 where
differences observed are smaller, and sometimes negligible. As the first of these reports
surfaced as meeting abstracts or publications, many organizational (normative) treatment
guidelines underwent review and were modified in response to them.3,31–33 The WHO
guidelines were of greatest importance to HPTN 052 because of the multinational nature of
the study.3,31 However, it should be emphasized that the countries that participated in HPTN
052 did not uniformly follow the evolving WHO Guidelines (see Table). The country
decisions were predicated on their own expert response to the strength of evidence, and the
general lack of availability of enough ART to follow WHO guidelines if they were put into
place. In 2009, investigators working in Haiti reported that subjects initiating ART at a
median CD4 count of 287 cells/mm3 did considerably better than those delaying ART until
a median CD4 count of 160 cells/mm3.17 While the data from this Comprehensive
International Program of Research on AIDS (CIPRA) Haiti study were compelling,
understanding the potential implications of these data for HPTN 052 required considering a
variety of questions, beginning with the external validity of the findings. Were the
populations in the CIPRA Haiti and HPTN 052 studies so similar that the results applied to
the HPTN 052 study? Were the study designs so similar that the CIPRA Haiti results
addressed the “when to start” question in HPTN 052?
On careful examination it became clear that there were important differences in the two
studies. In short, ART was initiated in subjects in HPTN 052 at higher CD4 counts than in
the CIPRA Haiti study in both the immediate and delayed arm. Ultimately, in HPTN 052,
the median CD4 count for the infected partner was 442 cells/mm3 in the immediate arm and
428 cells/mm3 in the delayed arm; ART was initiated in the delayed arm at a CD4 count
median of 221 cells/mm3 (Range: 199–249 cells/mm3)1. Nevertheless, the CIPRA Haiti
results and the anticipated changes in WHO guidelines expected to specify earlier initiation
of ART, led NIAID to request an urgent DSMB meeting in July 2009 to consider the
aggregate data. The primary purpose of this deliberation was to protect the well-being of the
subjects enrolled in the trial; here was a secondary but critical obligation to protect the
integrity of the trial, if appropriate. These deliberations emphasize the constant tension
between the need for modification of clinical and public health guidelines in response the
best available evidence, and the generation of better evidence: if randomized controlled
trials were routinely discontinued because of observational data or changing expert belief,
many critical trials would not come to completion. In other words, the opportunity to obtain
a higher level of evidence to address critical questions would be foreclosed.
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Upon review of all the internal and external data, the DSMB saw no evidence of harm to the
HPTN 052 subjects and the study was permitted to continue without modification. However,
in November of 2009, when new “Rapid Advice” WHO guidelines were released, which
recommended that ART be initiated at or before a CD4 count falls below 350 cells/mm3,31
all couples enrolled in the study were provided information about the new guidelines.
Despite uniformity in this approach across the study sites, Kenya, one of the participating
countries in HPTN 052 with a site in partnership with the Centers for Disease Control-
sponsored Kenya Medical Research Institute, adopted the new WHO guidelines in late 2010.
The CDC felt that a change in country guidelines to comport with the international
guidelines should be endorsed, and that the study participants should be provided with ART
to be consistent with these guidelines. Given the desire to maintain uniformity across all
sites, consideration was given to discontinuation of the study site, but the CDC declined this
option. As an alternative, participants at the site were given information about the WHO and
country guidelines and index participants in the delayed arm were told how to obtain ART
outside the study at the country-recommended CD4 count level should they choose to seek
it. Eight (8) participants elected to do so; for purposes of analysis of data, those changes in
treatment were considered protocol violations.
Ethical Challenges based on Trial Results: Delivering the Benefits
In April 2011, the DSMB observed that there was significant benefit to subjects in the early
ART arm of HPTN 052 and recommended that the results be made public as soon as
possible. Before this could transpire, decisions needed to be made about how to manage
subjects in the delayed ART arm. Based on the results, the study team was challenged to
initiate ART in delayed arm subjects at a CD4 count higher than in-country or WHO
guidelines. In addition, it was recognized that if participants in HPTN 052 were initiating
ART at a higher CD4 count than specified in country guidelines, there might be difficulty in
transitioning subjects onto locally-provided ART at the end of the study. This was discussed
with each site and country-by-country strategies to assure continued therapy after the trial
were developed.
The time of initiation of ART in response to CD4 count in HPTN 052 was modified several
times during the course of the study (See Figure), emphasizing the difficulty of guidance in
the absence of higher level evidence. When the HPTN 052 study was being developed,
several IRBs questioned the wisdom of initiating ART before the CD4 count fell below 200
cells/mm3, which was the standard of care for asymptomatic patients in 2002 when the
safety of the earlier initiation of ART had not been well established34. As described earlier,
by 2009 the belief about the ideal time to start treatment had evolved so much as to
jeopardize the continuation of the trial, although no high level evidence to support this
position had yet surfaced. The HPTN 052 trial results themselves demonstrated some degree
of benefit at a higher CD4 count than recommended in 2009 WHO guidelines, and certainly
beyond the resources of most countries participating in HPTN 052. But to allow the study
subjects to realize the benefits of the trial the investigators and the sponsor were required to
generate their own unique standard of care, hoping that guidelines and policies would follow
suit. In fact, in 2011, PEPFAR announced new guidance consistent with the results of HPTN
052.35 Similarly, WHO conducted a consultation in 2011 and is expected to issue new ART
guidelines in 201236).
Linked and Unlinked Transmission
The primary endpoint of HPTN 052 requires the establishment of virally linked and
unlinked transmission events.1 While transmission linkage information is important in
understanding the study results, whether to communicate such results to participants is
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another matter. After considering the merits of disclosing linkage information to
participants, a decision was made to keep it confidential. The justification for doing so is
based on the potential harms related to disclosure or non-disclosure. Any potential benefits
for the disclosure to the index subject would derive from having information about sexual
activity outside the partnership that would then translate into engaging in safer sexual
practices to minimize the chance of sexually transmitted infections. Conversely, revealing an
unlinked transmission could lead to harm and even physical violence to the newly infected
subject. In addition, each member of the couples participating in the study gave individual
consent, which stipulated that any information about sexual activity would be kept
confidential from the other member of the couple. Parenthetically, couples with unlinked
transmission were more likely to acknowledge multiple sexual partners.37, 38
Concluding Comments
In May 2011, results of HPTN 052 were made available to the sites, the study subjects, and
the public after median 1.7 years of follow-up1. But as mentioned earlier, the study was
designed to measure not only the magnitude, but also the durability of ART benefit.
Regardless of accelerated use of ART in the delayed arm, the study has the statistical power
to address these questions. In particular, will ART continue to offer a prevention benefit to
an HIV negative partner with the reliability observed in the first two years of the study?
Accordingly, the study will continue until 2015 as originally planned.
The HPTN 052 trial encountered a range of ethical challenges, some anticipated and some
surprising. The investigators worked closely with the local IRBs to sort through the issues
required for continuing approval of study implementation. The experience from HPTN 052
suggests that a prospective “ethics plan” comparable to a statistical analysis plan,
anticipating the challenges and envisioning potential scenarios, is a good idea. Accordingly,
HPTN appoints an ethics representative to each protocol team as the protocols are being
developed to address ethical concerns that occur in real time.16 The most important ethics
lesson from HPTN 052 was the constant threat to the study from observational and
ecological results stemming from huge amounts of emerging data generated by investigators
working on HIV, and the use of such data in guideline adjustments made by agencies and
their experts based on the best available evidence. As these necessary changes were made,
they threatened the very research that might support or refute the recommendations
themselves. Certainly this concern is not unique to HPTN 052, and there is no way to
abrogate this tension. Do ongoing studies that do not adhere to guideline revisions made
during the course of the study de facto become unethical? Unfortunately, a definitive yes or
no answer to this question in the abstract is impossible. So the ethical analysis hinges upon
what circumstances should new evidence lead to the termination of a clinical trial. Making
these determinations is largely the responsibility of a knowledgeable independent DSMB. In
the case of HPTN 052 the DSMB (which met 11 times during the course of the study)
played a central and critical role. We believe the system in place actually works as long as
the investigators, IRBs and the DSMB maintain good communication39. We believe that the
“ethical odyssey” of HTN 052 is a demonstration of the success of the current system of
research oversight.
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Table 1
HPTN 052 Implementation Status of WHO 2009 Guidelines for ART Initiation*
Site Implementation Status
SOUTH AMERICA
Brazil Threshold is at CD4 <350
ASIA
India Threshold is currently at CD4 <350 for HIV/TB (pulm) co-infected, and pregnant women with WHO stage 3 disease, and
Stage 4 disease or HIV with extra-pulmonary TB initiate ART irrespective of CD4 cell count. General population threshold to
increase to CD4 < 350 soon.
Thailand Current CD4 threshold for the general population is <200. Threshold increase to CD4 <350 for asymptomatic HIV positive
person will be reconsidered next year (2012). In order to initiate ART now at CD4 <350, a person needs to have some specific
illnesses that are related to HIV/AIDS or WHO stage 4 diseases.
AFRICA
Botswana Threshold remains at CD4 <250. Botswana National Subcommittee on Clinical Guidelines is awaiting assurance of resources
before considering increasing the threshold.
Kenya Threshold increased to CD4 <350 in late 2010, and is currently being implemented at local clinics.
Malawi Current CD4 threshold for the general population is <250. Threshold is currently at CD4 <350 for pregnant and breastfeeding
women. Any person with WHO stage 3 or stage 4 disease is eligible regardless of CD4 count.
South Africa Threshold remains at CD4 <350 for HIV/TB co-infected, and pregnant women with CD4 <350 or have WHO stage 3 or 4
disease.
Zimbabwe Due to resource constraints, the MOH released guidelines in March 2011 for a phased-approach of implementation of ART
initiation for CD4 <350 over next three years, starting 01 April 2011.
*
Current as of April 2011
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